Operating
Other Non-Cash Items
Regeneron Pharmaceuticals Other Non-Cash Items increased by 59.4% to -$55.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1637.5%, from -$3.20M to -$55.60M. Over 4 years (FY 2021 to FY 2025), Other Non-Cash Items shows an upward trend with a -30.1% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
Metric ID:
mrk_other_noncash_income_expenseHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$163.90M | -$71.80M | -$304.30M | -$84.30M | -$54.00M | -$60.70M | -$169.00M | -$20.60M | -$8.60M | $11.80M | $17.50M | -$100.00K | $3.00M | $29.00M | -$68.00M | -$3.20M | $20.90M | -$16.30M | -$136.90M | -$55.60M |
| QoQ Change | — | +56.2% | -323.8% | +72.3% | +35.9% | -12.4% | -178.4% | +87.8% | +58.3% | +237.2% | +48.3% | -100.6% | >999% | +866.7% | -334.5% | +95.3% | +753.1% | -178.0% | -739.9% | +59.4% |
| YoY Change | — | — | — | — | +67.1% | +15.5% | +44.5% | +75.6% | +84.1% | +119.4% | +110.4% | +99.5% | +134.9% | +145.8% | -488.6% | <-999% | +596.7% | -156.2% | -101.3% | <-999% |
Range-$304.30M – $29.00M
CAGR-20.4%
Avg YoY Growth-249.4%
Median YoY Growth+71.3%
Other Non-Cash Items at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's other non-cash items?
- Regeneron Pharmaceuticals (REGN) reported other non-cash items of -$55.60M in Q1 2026.
- How has Regeneron Pharmaceuticals's other non-cash items changed year-over-year?
- Regeneron Pharmaceuticals's other non-cash items decreased by 1637.5% year-over-year, from -$3.20M to -$55.60M.
- What is the long-term trend for Regeneron Pharmaceuticals's other non-cash items?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's other non-cash items has grown at a -30.1% compound annual growth rate (CAGR), from -$568.70M to -$135.50M.